Eli Lilly Just Raised the Bar — Again

Forget 15%. Forget 20%. Eli Lilly announced last week that the highest dose of its newest weight-loss drug produced more than 30% body weight reduction in trial participants, according to the Washington Post.

That's the equivalent of gastric bypass surgery in a pill — or more precisely, an injection. A surgical procedure that requires cutting into a human being and rerouting their digestive system has been the gold standard for severe obesity for decades. A drug just matched it.

This marks a significant shift in the competitive landscape. CagriSema produced 20% results, and retatrutide is in the pipeline. Lilly has now surpassed both with a single data release.

The FDA Slapped Novo Nordisk — And Most Coverage Buried It

One thing the "GLP-1s are amazing" coverage keeps glossing over: In early March 2026, the FDA sent a formal warning letter to Novo Nordisk — the maker of Ozempic and Wegovy — alleging the company failed to properly report and/or follow up on three deaths of individuals taking semaglutide, according to Scientific American.

Three deaths. Not disclosed. Not followed up on. By one of the largest pharmaceutical companies on earth.

This isn't a fringe claim. This is the FDA. In writing. To Novo Nordisk.

The Washington Post's opinion coverage spent zero words on this. Harvard Gazette didn't mention it either. When the media narrative around a drug class is relentlessly positive, inconvenient regulatory actions tend to get deprioritized.

Were the deaths caused by semaglutide? Unknown. Novo Nordisk allegedly didn't report them properly so we could find out.

Harvard Researchers: This Drug Class Is Rewriting Medicine

With that caveat on the table, the science coming out of Harvard is genuinely striking.

Dr. Muthiah Vaduganathan, cardiologist at Brigham and Women's Hospital and Harvard Medical School faculty, told the Harvard Gazette that GLP-1 drugs are now understood to influence "the central cardio-kidney metabolic process" — meaning they don't just treat one disease, they address a root driver of multiple diseases simultaneously.

"Their role is now being understood to be much, much more fundamental to human health, and to promoting longevity and preventing chronic illness progression," Vaduganathan said.

Dr. Nils Krüger, an instructor at Harvard Medical School and Brigham and Women's Hospital, found that GLP-1s showed a 40% relative risk reduction for heart failure with preserved ejection fraction compared to older diabetes medication.

"That's something you don't see for every drug," Krüger said, according to the Harvard Gazette.

He's also tracking benefits in reducing major adverse cardiovascular events — cardiovascular death, nonfatal heart attacks, nonfatal strokes. These are clinical trial results.

The New Frontier: Addiction, Liver Disease, Sleep Apnea

Researchers are now investigating GLP-1s for substance use disorders, chronic liver disease, and obstructive sleep apnea — conditions that have had few effective treatment options for years, according to the Harvard Gazette.

Those three conditions affect tens of millions of Americans and cost the healthcare system billions annually. If GLP-1s show even modest benefits there, the fiscal implications are enormous.

Scientific American notes that the drug class's expansion has also spawned a flood of non-FDA-approved copycat drugs hitting the market. Compounding pharmacies have been churning out semaglutide alternatives that haven't gone through the same safety scrutiny. The FDA has been playing whack-a-mole.

Consumers buying discount GLP-1 alternatives online are taking on unknown risks.

What Mainstream Media Is Getting Wrong

The coverage split here is revealing. Left-leaning outlets like the Washington Post are running opinion pieces framing GLP-1s as nearly miraculous — which makes the FDA's warning letter to Novo Nordisk even more glaring by its absence.

Right-leaning media, meanwhile, often frames GLP-1 drugs through a "personal responsibility" lens — if people just exercised and ate right, they wouldn't need this. That framing ignores that obesity has complex biological drivers, and that a drug cutting cardiac death risk by 40% is a public health win regardless of your politics.

Both miss the core story: an extraordinary drug class with extraordinary potential and real, unresolved safety questions that aren't being asked loudly enough.

What This Means For You

If you're one of the millions considering or currently on a GLP-1 drug, consider the following:

The upside is real. The 30% weight loss number from Lilly is significant. The cardiovascular data is impressive. Researchers at top institutions are following the data.

But Novo Nordisk is now under formal FDA scrutiny for death reporting failures. The long-term safety profile of these drugs — especially at higher doses — is still being written in real time.

Three unreported deaths doesn't mean GLP-1s are dangerous. It means a pharmaceutical company may have failed to do its job. Those are very different things. Until that investigation concludes, anyone on these drugs deserves to know it's happening.

The drugs may be revolutionary. The companies selling them are still companies.